💨 Abstract

Datar Cancer Genetics launched Target-MRD, an advanced blood test for solid organ cancers. It combines tumor-agnostic next-generation sequencing and tumor-informed droplet digital PCR for personalized, accurate, and effective monitoring of molecular residual disease. The test detects minimal residual disease at the molecular level to assist early intervention by oncologists.

Courtesy: theprint.in

Summarized by Einstein Beta 🤖